Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H.

Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Erratum in: Lancet. 2011 Apr 2;377(9772):1154.

PMID:
21176949
2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.

Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD007678. doi: 10.1002/14651858.CD007678.pub2. Review.

PMID:
22258971
4.

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J.

Health Technol Assess. 2012;16(37):1-253, iii-iv. Review.

5.

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, Cohen A, Shpilberg O.

J Natl Cancer Inst. 2009 Feb 18;101(4):248-55. doi: 10.1093/jnci/djn478. Review.

6.

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.

Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S, Dundar Y, Hockenhull J, Proudlove C, Chu P.

Pharmacoeconomics. 2013 May;31(5):403-13. doi: 10.1007/s40273-013-0043-8. Review.

7.

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.

Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, Pettengell R, Witzens-Harig M, Shpilberg O.

J Natl Cancer Inst. 2011 Dec 7;103(23):1799-806. doi: 10.1093/jnci/djr418. Review.

8.

Rituximab as maintenance therapy for patients with follicular lymphoma.

Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006552. doi: 10.1002/14651858.CD006552.pub2. Review.

PMID:
19370640
9.

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.

Boland A, Bagust A, Hockenhull J, Davis H, Chu P, Dickson R.

Health Technol Assess. 2009 Sep;13 Suppl 2:41-8. doi: 10.3310/hta13suppl2/06. Review.

10.

Maintenance therapy in follicular lymphoma.

Michallet AS, Coiffier B, Salles G.

Curr Opin Oncol. 2011 Sep;23(5):449-54. doi: 10.1097/CCO.0b013e3283490515. Review.

PMID:
21734580
11.

A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas.

Nabhan C, Ollberding NJ, Villines D, Chiu BC, Caces DB, Valdez TV, Ghielmini M, Hsu Schmitz SF, Smith SM.

Leuk Lymphoma. 2014 Jun;55(6):1288-94. doi: 10.3109/10428194.2013.839787. Review.

PMID:
23998254
12.

Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.

Reagan PM, Friedberg JW.

Curr Treat Options Oncol. 2015 Jul;16(7):32. doi: 10.1007/s11864-015-0351-7. Review.

PMID:
26031546
13.

Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.

Croxtall JD.

Drugs. 2011 May 7;71(7):885-95. doi: 10.2165/11206720-000000000-00000. Review.

PMID:
21568365
14.

Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report.

Croxtall JD.

BioDrugs. 2011 Oct 1;25(5):329-31. doi: 10.2165/11207200-000000000-00000. Review. No abstract available.

PMID:
21942917
15.

'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy?

Hagemeister FB.

BioDrugs. 2012 Dec 1;26(6):363-76. doi: 10.2165/11634320-000000000-00000. Review.

PMID:
23057946
16.

Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?

Kahl B.

Hematology Am Soc Hematol Educ Program. 2012;2012:433-8. doi: 10.1182/asheducation-2012.1.433. Review.

PMID:
23233615
17.

Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.

Buchegger F, Larson SM, Mach JP, Chalandon Y, Dietrich PY, Cairoli A, Prior JO, Romero P, Speiser DE.

Clin Dev Immunol. 2013;2013:875343. doi: 10.1155/2013/875343. Review.

18.

Treatment approaches to asymptomatic follicular lymphoma.

Sarkozy C, Salles G.

Expert Rev Hematol. 2013 Dec;6(6):747-58. doi: 10.1586/17474086.2013.860355. Review.

PMID:
24219551
19.

[Recurrent upper respiratory tract infections during and after rituximab therapy].

Jacobs BA, Opdam FL, Rodenhuis S, Baars JW.

Ned Tijdschr Geneeskd. 2015;159:A8546. Review. Dutch.

PMID:
25850451
20.

Effect of rituximab on adult Burkitt's lymphoma: a systematic review and meta-analysis.

Nie M, Wang Y, Bi XW, Xia Y, Sun P, Liu PP, Li ZM, Jiang WQ.

Ann Hematol. 2016 Jan;95(1):19-26. doi: 10.1007/s00277-015-2501-1. Review.

PMID:
26423805
Items per page

Supplemental Content

Support Center